Jessica Frau1, Margherita Carai2, Giancarlo Coghe2, Giuseppe Fenu2, Lorena Lorefice2, Giorgio La Nasa3, Elena Mamusa2, Adriana Vacca3, Maria Giovanna Marrosu2, Eleonora Cocco2. 1. Department of Medical Sciences and Public Health, Multiple Sclerosis Center, ATS Sardegna, Ospedale Binaghi, University of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy. jessicafrau@hotmail.it. 2. Department of Medical Sciences and Public Health, Multiple Sclerosis Center, ATS Sardegna, Ospedale Binaghi, University of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy. 3. Department of Medical Sciences and Public Health, Bone Marrow Transplant Center, University of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy.
Abstract
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) is used in aggressive relapsing and progressive multiple sclerosis (MS). The multicentre studies and case series reported have relatively short follow-up. AIM: To evaluate long-term effect and safety of HSCT in MS. MATERIALS AND METHODS: Patients referred to the MS centre of Cagliari and undergoing HSCT were included. Variations in relapses and EDSS before and after HSCT were evaluated by Wilcoxon test. A descriptive analysis was made for other clinical data. RESULTS: Nine patients (female 6, males 3; 5 relapsing-remitting, 2 secondary progressive, 1 primary progressive, and 1 progressive relapsing) performed HSCT (1999-2006). The median follow-up was 11 years (11-18). Eight patients underwent aHSCT, seven using a low intensity conditioning regimen, and one an intermediate intensity. The primary progressive underwent allogeneic HSCT, due to onco hematological disease. The relapses number decreased in the 2 years following the procedure compared to the two preceding years (p = 0.041). New relapses or disease progressions were observed after a range of 7 (low intensity regimen)-118 (intermediate intensity) months. At last follow-up, the EDSS was stable in two patients, improved in two, and worse in five (maximum 2 EDSS in one patient). Six patients showed new lesions, and seven gadolinium-enhancing on brain MRI after a mean of 23.3 and 19.8 months, respectively. Two serious adverse events were reported: melanoma, and progressive multifocal leukoencephalopathy. CONCLUSIONS AND DISCUSSION: Our results confirm in a long follow-up the efficacy of HSCT in reducing relapses and disability progression. The risk/benefit profile is better for intermediate intensity regimens.
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) is used in aggressive relapsing and progressive multiple sclerosis (MS). The multicentre studies and case series reported have relatively short follow-up. AIM: To evaluate long-term effect and safety of HSCT in MS. MATERIALS AND METHODS:Patients referred to the MS centre of Cagliari and undergoing HSCT were included. Variations in relapses and EDSS before and after HSCT were evaluated by Wilcoxon test. A descriptive analysis was made for other clinical data. RESULTS: Nine patients (female 6, males 3; 5 relapsing-remitting, 2 secondary progressive, 1 primary progressive, and 1 progressive relapsing) performed HSCT (1999-2006). The median follow-up was 11 years (11-18). Eight patients underwent aHSCT, seven using a low intensity conditioning regimen, and one an intermediate intensity. The primary progressive underwent allogeneic HSCT, due to onco hematological disease. The relapses number decreased in the 2 years following the procedure compared to the two preceding years (p = 0.041). New relapses or disease progressions were observed after a range of 7 (low intensity regimen)-118 (intermediate intensity) months. At last follow-up, the EDSS was stable in two patients, improved in two, and worse in five (maximum 2 EDSS in one patient). Six patients showed new lesions, and seven gadolinium-enhancing on brain MRI after a mean of 23.3 and 19.8 months, respectively. Two serious adverse events were reported: melanoma, and progressive multifocal leukoencephalopathy. CONCLUSIONS AND DISCUSSION: Our results confirm in a long follow-up the efficacy of HSCT in reducing relapses and disability progression. The risk/benefit profile is better for intermediate intensity regimens.
Authors: Maria Pia Sormani; Paolo A Muraro; Irene Schiavetti; Alessio Signori; Alice Laroni; Riccardo Saccardi; Gian Luigi Mancardi Journal: Neurology Date: 2017-04-28 Impact factor: 9.910
Authors: Eva Krasulová; Marek Trneny; Tomás Kozák; Blanka Vacková; David Pohlreich; David Kemlink; Petr Kobylka; Ivana Kovárová; Petra Lhotáková; Eva Havrdová Journal: Mult Scler Date: 2010-03-29 Impact factor: 6.312
Authors: A Fassas; A Anagnostopoulos; A Kazis; K Kapinas; I Sakellari; V Kimiskidis; A Tsompanakou Journal: Bone Marrow Transplant Date: 1997-10 Impact factor: 5.483
Authors: Bonaventura Casanova; Isidro Jarque; Francisco Gascón; Juan Carlos Hernández-Boluda; Francisco Pérez-Miralles; Javier de la Rubia; Carmen Alcalá; Jaime Sanz; Javier Mallada; Angeles Cervelló; Arantxa Navarré; María Carcelén-Gadea; Isabel Boscá; Sara Gil-Perotin; Carlos Solano; Miguel Angel Sanz; Francisco Coret Journal: Neurol Sci Date: 2017-04-10 Impact factor: 3.307
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Susan J van Rensburg; Ronald van Toorn; Rajiv T Erasmus; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Merlisa C Kemp; Penelope Engel-Hills; Maritha J Kotze Journal: Metab Brain Dis Date: 2021-04-28 Impact factor: 3.584